2 employees
Phase 3 and Phase 2 ongoing in lower gastrointestinal disorders
2007
$9.5M
from 3 investors over 3 rounds
RDD Pharma Ltd. raised $9.5M on November 16, 2017
Investors: Pharmascience, Capital Point Ltd (CPTP) and OrbiMed Advisors